-
Dangote, Nigeria's oil tycoon rewriting Africa's story
-
Two charged with UK security offences over airbase plot: police
-
Carrick to remain Man Utd boss for Chelsea clash: reports
-
Maresca defends Donnarumma, Guehi after Man City defeat
-
Greenhouse gas levels hit new record highs in 2025: UN
-
Nordic leaders call Putin as local truce begins in Ukraine
-
Rybakina looking to clinch year-end number one in Tokyo
-
Osaka unveils crane outfit in Tokyo before win over Paolini
-
Tech firms track Wall St rally on mixed day for stock markets
-
Ronaldo in line for Portugal return after fallout with coach
-
Kane says Ballon d'Or win 'feels like a dream' as tributes pour in
-
Norway media take legal action to block Meta from using content
-
HSBC profit jumps on higher rates, lower costs
-
Bayern praise 'humble' Kane after Ballon d'Or win
-
Rams rediscover offensive balance in 35-21 victory over Raiders
-
Colts retain Daniel Jones as starter despite continued offensive struggles
-
Mercedes-Benz cuts 2026 profit outlook on tough China market
-
Madushanka wrecks Pakistan as Sri Lanka press for final slot
-
Reparations calls follow Charles on tough Caribbean trip
-
Destructive Abhishek 113 leads India to series win over New Zealand
-
Jammu and Kashmir ministers resign before planned council expansion
-
Norway, Finland leaders hold 'frank and substantive' talk with Putin
-
Germany, EU, stable investment stops despite upheaval: Merz
-
Wall Street faces earnings and Fed tests after turbulent technology-led week
-
China brands drop Mbappe for 'offending national sentiments'
-
Ukraine, Russia say US-brokered truce holding in ravaged city
-
India orders evacuations as Cyclone Arnab looms
-
Police form SIT after vehicles in Rahul Gandhi convoy collide on expressway
-
Dutch broadcaster pulls out of Eurovision over Israel 'sensitivities'
-
Delhi grants minimum monthly pay and DA to about 4,000 MCD health workers
-
Critical coal inventories affect nearly half of India’s domestic power plants
-
Ather Energy shares climb 14% after quarterly profit and expansion plan
-
FCNR(B) deposit drive puts sharper margin pressure on private banks
-
Gold ETF flows turn negative after 13 weeks as bullion loses 4%
-
Noel Tata requests records of September 17 Tata Sons board meeting
-
Pakistan's last antique restorers give old treasures new life
-
Reparations calls to dog King Charles's tough Caribbean trip
-
India braces for Cyclone Arnab with evacuations
-
Global rates and foreign outflows remain key risks for Indian markets
-
Steel Strips Wheels gains 36% in two sessions on growth outlook
-
Neha Nagar says ₹3 crore can fund retirement with disciplined planning
-
Cavs edge T'Wolves in overtime despite superb Edwards
-
Vikas Satija says steady SIP flows shielded Indian equities from deeper losses
-
Prescott fires Cowboys to 38-21 win over plummeting Eagles
-
Brewers rout Rays to reach brink of World Series sweep
-
Kuwait padel chief hails national showing at Premier Padel Major
-
Mbappe dropped by Chinese brands for 'offending national sentiments'
-
Britain prepares constrained budget as debt and defence pressures mount
-
Kuwait exhibition presents Ukraine’s Islamic heritage and cultural ties
-
Valkyries beat Dream to reach brink of WNBA title
Moderna Recognized by TIME as One of the World's Most Impactful Companies
CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies. The recognition highlights the Company's work as a pioneer of mRNA technology and its focus on delivering meaningful benefits for patients and society.
"We are honored to be recognized by TIME as one of the world's most impactful companies," said Stéphane Bancel, Chief Executive Officer of Moderna. "This reflects the dedication of our team to our mission and advancing mRNA science for patients. We remain focused on developing innovative medicines to address significant unmet needs, expanding the reach of our platform across infectious diseases, oncology and rare diseases, and strengthening pandemic preparedness to deliver lasting impact for people and communities around the world."
In 2026, Moderna received approval in Europe for its fourth product, mCOMBRIAX®, a flu plus COVID combination vaccine. As its product portfolio grows, the Company continues to invest in its long-term strategic partnerships with the United Kingdom, Canada and Australia to support pandemic readiness by expanding manufacturing capacity and minimizing response times.
Moderna recently marked the fourth anniversary of the Moderna Charitable Foundation and published its fourth annual Impacting Human Health Report. Through its mRNA Access program, the Company partners with the scientific community to offer researchers the use of its mRNA technology to explore new vaccines against emerging or neglected infectious diseases. Since its launch in 2022, the program has grown to include 35 institutions worldwide.
Presented by TIME and Statista, this ranking is grounded in a science-based methodology. The Upright Project's Net Impact Model evaluates companies based on the net-positive contributions of their products and services across four key dimensions: Society, Knowledge, Health, and Environment, which are measured throughout the full value chain and comparable across industries and regions.
For the complete feature along with individual company rankings, please visit time.com.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
[email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
O.M.Souza--AMWN